Cogent Biosciences

Biotech

cogentbio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
28
2 granted · 26 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1911Wise Trading Technologies, Inc.—$85K
1912GRO BIOSCIENCES INC——
1913SET THERAPEUTICS INC——
1914Cogent Biosciences——
1915RIPARIAN PHARMACEUTICALS INC—$500K
1916Origin Protocol, Inc.—$38M
1917NGM Bio Holdings, Inc.—$73M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 28
  • Compounds For Fgfr Inhibitionapplication
  • Compounds For Fgfr Inhibitiongranted
  • PI3K Inhibitorsapplication
  • ERBB2 Inhibitorsapplication
  • PI3K Inhibitorsgranted
  • Compounds For Fgfrs Inhibitorsapplication
  • Bezuclastinib Formulationsapplication
  • Kras Inhibitorsapplication
  • ERBB2 Inhibitorsapplication
  • Kras Inhibitorsapplication
  • Compounds For Fgfrs Inhibitorsapplication
  • Compounds For Fgfr Inhibitionapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.